Macugen pegaptanib: Phase IV data

In an open-label, uncontrolled, U.S. Phase IV trial in 20 patients, Macugen led to a mean gain of 14 letters from baseline to week 54 in BCVA score. Macugen also decreased center point thickness by 20...